Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Finding the right unprofitable companies is difficult, which is why we started StockStory - to help you navigate the market. Keeping that in mind, here is one unprofitable company with the potential to become an industry leader and two that could struggle to survive.

Two Stocks to Sell:

Acadia Healthcare (ACHC)

Trailing 12-Month GAAP Operating Margin: -28%

With a network of over 250 facilities serving patients in 38 states and Puerto Rico, Acadia Healthcare (NASDAQ: ACHC) operates facilities providing mental health and substance use disorder treatment services across the United States.

Why Do We Think ACHC Will Underperform?

1. Weak admissions over the past two years show it’s struggled to increase its sales volumes and had to rely on price increases
2. Earnings per share fell by 6.1% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
3. 18.9 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

Acadia Healthcare is trading at $22.78 per share, or 15.6x forward P/E. If you’re considering ACHC for your portfolio, see our FREE research report to learn more.

Mobileye (MBLY)

Trailing 12-Month GAAP Operating Margin: -23.2%

With its EyeQ chips installed in over 200 million vehicles worldwide, Mobileye (NASDAQ: MBLY) develops advanced driver assistance systems and autonomous driving technologies that help vehicles detect and respond to road conditions.

Why Do We Steer Clear of MBLY?

1. Annual sales declines of 4.6% for the past two years show its products and services struggled to connect with the market during this cycle
2. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 5.2 percentage points
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

Mobileye’s stock price of $7.91 implies a valuation ratio of 29.4x forward P/E. Read our free research report to see why you should think twice about including MBLY in your portfolio.

One Stock to Watch:

Braze (BRZE)

Trailing 12-Month GAAP Operating Margin: -19.9%

With its technology powering interactions with 6.2 billion monthly active users across the digital landscape, Braze (NASDAQ: BRZE) provides a platform that helps brands build and maintain direct relationships with their customers through personalized, cross-channel messaging and engagement.

Why Could BRZE Be a Winner?

1. Impressive 25.6% annual revenue growth over the last two years indicates it’s winning market share
2. Billings have averaged 22.4% growth over the last year, showing it’s securing new contracts that could potentially increase in value over time
3. Estimated revenue growth of 19.2% for the next 12 months implies its momentum over the last two years will continue

At $19.38 per share, Braze trades at 2.5x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.